Seattle Genetics discovers and develops monoclonal antibody, or mAb-based therapeutics to treat cancer and related diseases. The company has four technologies: engineered mAbs, mAb-drug conjugates,single-chain immunotoxins and ADEPT. We have built a strong corporate culture around the values of integrity, scientific excellence, teamwork, innovation and mutual respect. Seattle Genetics embodies an entrepreneurial spirit that advances breakthrough therapies, which is why we are an acknowledged leader today in antibody-drug conjugate technology.